2025
Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).
Huppert L, Ellisen L, Anders C, Isaacs C, Santa-Maria C, Anampa J, DeMichele A, Balic M, Specht J, Lustberg M, Wolff A, Krop I, Rugo H. Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067). Journal Of Clinical Oncology 2025, 43: tps1137-tps1137. DOI: 10.1200/jco.2025.43.16_suppl.tps1137.Peer-Reviewed Original ResearchMetastatic breast cancerReal-world overall survivalProgression free survivalHER2-negative metastatic breast cancerMetastatic triple negative breast cancerStandard of careAntibody-drug conjugatesDisease control rateDuration of responseOverall survivalBreast cancerPatient-reported outcomesFree survivalHER2 negative metastatic breast cancerTreatment strategiesHormone receptor-positive/HER2-negativeNegative metastatic breast cancerTriple negative breast cancerEffective new treatment strategyPhase III clinical trialsRegistry study of patientsKaplan-Meier methodNegative breast cancerIII clinical trialsNew treatment strategies
2020
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Herbst R, Tsuboi M, John T, Grohé C, Majem M, Goldman J, Kim S, Marmol D, Rukazenkov Y, Wu Y. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Journal Of Clinical Oncology 2020, 38: lba5-lba5. DOI: 10.1200/jco.2020.38.18_suppl.lba5.Peer-Reviewed Original ResearchDisease-free survivalComplete tumor resectionDFS hazard ratioAdjuvant chemotherapyData cutoffHazard ratioOverall survivalTumor resectionAdjuvant osimertinibDFS ratesEGFRm NSCLCEGFR-TKISafety profileEGFR mutation-positive NSCLCEffective new treatment strategyResected stage IISafety of osimertinibEarly-stage diseaseMutation-positive NSCLCNew treatment strategiesUnplanned interim analysisEligible ptsIIIA NSCLCNSCLC presentPS 0/1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply